Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,778 total articles

Pilgrim’s Pride Corporation Announces Pricing of Tender Offer for Its 6.250% Senior Notes Due 2033

Pilgrim’s Pride Corporation Announces Pricing of Tender Offer for Its 6.250% Senior Notes Due 2033

Pilgrim's Pride Corporation announced the pricing details for its previously announced tender offer of up to $250 million aggregate principal amount of its outstanding 6.250% Senior Notes due 2033. The tender offer is oversubscribed, resulting in a pro rata acceptance of approximately 53%. The company expects to settle the accepted notes on April 1…

Parsons Selected to Lead Design of $409M Roosevelt Bridge Replacement

Parsons Selected to Lead Design of $409M Roosevelt Bridge Replacement

Parsons Corporation has been selected as the lead designer for the $409 million Roosevelt Bridge Replacement over Lake Texoma in Oklahoma. The project is backed by the largest federal grant awarded by Oklahoma in 2024, emphasizing the importance of infrastructure modernization. With extensive experience in bridge design, Parsons is set to deliver a…

Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron Pharmaceuticals and Telix Pharmaceuticals announced a strategic collaboration to co-develop and co-commercialize next-generation radiopharmaceutical therapies focused on oncology. The partnership leverages Regeneron's antibody discovery platforms and Telix's radiopharmaceutical development and manufacturing capabilities. The collaboration…

urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 — Potential Record 600-Player Pool, World-Class Marquee Talent, and Expected Appointment of Chris Gayle as Global Brand Ambassador

urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 — Potential Record 600-Player Pool, World-Class Marquee Talent, and Expected Appointment of Chris Gayle as Global Brand Ambassador

urban-gro, Inc., through its subsidiary Innovative Production Group, announces the upcoming Lanka Premier League Season 6 with a record 500-600 player registration pool featuring global cricket stars and T20 icon Chris Gayle as the expected global brand ambassador. This move signifies the company's entrée into the global T20 cricket arena, targetin…

National Healthcare Properties Announces Launch of Public Offering

National Healthcare Properties Announces Launch of Public Offering

National Healthcare Properties, Inc. announced a public offering of 38.5 million shares of its Class A common stock, aiming to raise capital through an IPO priced between $13.00 and $16.00 per share. The net proceeds will be used to repay $186 million in revolving credit facility debt, finance potential future property acquisitions, and cover gener…

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Kymera Therapeutics announced that its investigational drug KT-621 received Fast Track designation from the U.S. FDA for the treatment of moderate to severe eosinophilic asthma. KT-621, an oral STAT6 degrader, is currently in Phase 2b clinical trials for asthma and atopic dermatitis, with data expected in 2027. The designation may expedite developm…

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

Seer, Inc., a Nasdaq-listed proteomics company, announced receipt of a non-binding, unsolicited proposal from the Radoff-JEC Group to acquire all outstanding Class A shares for $2.25 per share plus a contingent value right. The group also nominated three director candidates for the upcoming 2026 Annual Meeting. The Seer Board will review the propos…

ImageneBio Announces $30 Million Private Placement

ImageneBio Announces $30 Million Private Placement

ImageneBio announced a $30 million private placement led by Coastlands Capital to fund further development of its lead immuno-modulatory candidate IMG-007 in alopecia areata and atopic dermatitis. The proceeds will support ongoing Phase 2b trials and late-stage development activities, highlighting investor confidence in IMG-007's differentiated mec…

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix announced positive additional 52-week data from its SOL-1 Phase 3 trial of AXPAXLI, showcasing unmatched durability and sustained disease control in treating wet age-related macular degeneration. The data reinforce AXPAXLI's superiority over aflibercept with significantly prolonged efficacy and favorable safety, underpinning the …

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

Spyre Therapeutics announced positive topline 12-week induction data from Part A of the Phase 2 SKYLINE trial for SPY001, an extended half-life anti-α4β7 antibody, showing statistically significant improvement in histopathology and clinical remission in moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a significant red…

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

NRx Pharmaceuticals has appointed Glenn Tyson as its first Chief Commercial Officer to lead commercialization efforts as the company anticipates approval of its preservative-free ketamine product and prepares for a new drug application submission to expand ketamine use for depression and suicidality. Tyson brings 25 years of industry experience, in…

Eldorado Gold Provides Q1 2026 Conference Call Details

Eldorado Gold Provides Q1 2026 Conference Call Details

Eldorado Gold Corporation will release its financial and operational results for the first quarter of 2026 on April 30, 2026, and will host a conference call on May 1, 2026. The company operates gold and base metals mining and exploration projects in Canada, Türkiye, and Greece, and its shares trade on both the TSX and NYSE American exchanges.

Caliber and PURE Pickleball & Padel Announce Building Permit Approval for World’s Largest Indoor Pickleball and Padel Facility

Caliber and PURE Pickleball & Padel Announce Building Permit Approval for World’s Largest Indoor Pickleball and Padel Facility

Caliber (Nasdaq: CWD), a US-based diversified real estate and digital asset management platform, announced that PURE Pickleball & Padel's 196,000-square-foot indoor sports facility in Scottsdale, Arizona, has received all required building permits. This milestone paves the way for groundbreaking, expected after construction financing closes. The fa…

Calavo Growers Declares Quarterly Dividend

Calavo Growers Declares Quarterly Dividend

Calavo Growers, Inc., a leader in fresh produce sourcing and processing, declared a quarterly cash dividend of $0.20 per share. The company amended the dividend record date to April 24, 2026, while maintaining the payment date of April 29, 2026. This adjustment complies with Nasdaq's notice requirements without changing dividend value or payment ti…

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics announced encouraging interim futility analysis results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel), an allogeneic CAR T therapy, in first-line consolidation for large B-cell lymphoma (LBCL). The cema-cel arm showed a 58.3% minimal residual disease (MRD) clearance rate versus 16.7% in the ob…

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

BullFrog AI Holdings announced a significant commercial feasibility agreement with a top 5 global pharmaceutical company to use its AI platform bfLEAP® to identify novel drug targets in major depressive disorder. The company also strengthened its balance sheet with recent financings to support operations into late 2027 and is advancing multiple dis…

ASP Isotopes Inc. Provides Business Update

ASP Isotopes Inc. Provides Business Update

ASP Isotopes Inc. presents a comprehensive business update highlighting operational milestones across its nuclear medicine, electronics, and nuclear energy platforms. The company anticipates first commercial shipments of several enriched isotopes including Silicon-28, Carbon-14, and Ytterbium-176 in 2026, expects to reach helium production capacity…